- To evaluate the lifetime cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors for treatment of high blood cholesterol levels.
- We added cost data to a validated coronary heart disease (CHD) prevention computer model that estimates the benefits of lifelong risk factor modification.
The updated model takes into account the costs of cholesterol reduction, the savings in CHD health care costs attributable to intervention, the additional non-CHD costs resulting from patients'living longer, and the beneficial effects of reducing CHD risk by reducing total cholesterol and increasing high-density lipoprotein cholesterol (HDL-C).
- Men and women aged 30 to 70 years who were free of CHD, had total cholesterol levels equal to the 90th percentile of the US distribution in their age and sex group, had HDL-C levels equal to the mean of the US distribution in their age and sex group, and were either with or without additional CHD risk factors.
Main Outcome Measures.
- Cost per year of life saved after discounting benefits and costs by 5% annually.
- The cost-effectiveness of HMG-CoA reductase inhibitors varied widely by age and sex and was sensitive to the presence of non-lipid CHD risk factors.
The additional non-CHD costs due to increased life expectancy may be significant for the elderly.
Mots-clés Pascal : Cardiopathie coronaire, Prévention, Economie santé, Inhibiteur enzyme, Coenzyme A, Reductase, Enzyme, Hypolipémiant, Chimiothérapie, Traitement, Homme, Appareil circulatoire pathologie
Mots-clés Pascal anglais : Coronary heart disease, Prevention, Health economy, Enzyme inhibitor, Coenzyme A, Reductase, Enzyme, Antilipemic agent, Chemotherapy, Treatment, Human, Cardiovascular disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0286892
Code Inist : 002B02N. Création : 01/03/1996.